Recent advances in the field of antibody-drug conjugates (ADCs) have led to successful approvals of therapeutics in a few cancer indications. However, there are certain limitations of ADCs that can potentially be solved using nanotechnology. At Glysantis, we envision the future of targeted therapeutic payload delivery using NanoDendrix™ technology. Armed with therapeutic payloads and targeting ligands, NanoDendrix™ particles have the potential to unleash the next generation of nanoparticle-drug conjugates. The technology is at the discovery stage and we have encouraging proofs-of-concept in payload attachment and linker chemistry.
Click here to download a non-confidential slide deck with more information about Glysantis' technology and pipeline